PRMTs and arginine methylation: cancer's best-kept secret?

J Jarrold, CC Davies - Trends in molecular medicine, 2019 - cell.com
Post-translational modification (PTM) of proteins is vital for increasing proteome diversity
and maintaining cellular homeostasis. If the writing, reading, and removal of modifications …

[HTML][HTML] Promising role of protein arginine methyltransferases in overcoming anti-cancer drug resistance

Y Zhu, T Xia, DQ Chen, X Xiong, L Shi, Y Zuo… - Drug Resistance …, 2024 - Elsevier
Drug resistance remains a major challenge in cancer treatment, necessitating the
development of novel strategies to overcome it. Protein arginine methyltransferases …

The emerging role of PRMT6 in cancer

Z Chen, J Gan, Z Wei, M Zhang, Y Du, C Xu… - Frontiers in …, 2022 - frontiersin.org
Protein arginine methyltransferase 6 (PRMT6) is a type I PRMT that is involved in epigenetic
regulation of gene expression through methylating histone or non-histone proteins, and …

[HTML][HTML] SUV39H1 deficiency suppresses clear cell renal cell carcinoma growth by inducing ferroptosis

J Wang, X Yin, W He, W Xue, J Zhang… - Acta Pharmaceutica Sinica …, 2021 - Elsevier
Clear cell renal cell carcinoma (ccRCC) is a common kidney malignancy characterized by a
poor prognosis. Suppressor of variegation 3–9 homolog 1 (SUV39H1), which encodes a …

A patent review of arginine methyltransferase inhibitors (2010–2018)

X Li, C Wang, H Jiang, C Luo - Expert opinion on therapeutic …, 2019 - Taylor & Francis
ABSTRACT Introduction: Protein arginine methyltransferases (PRMTs) are fundamental
enzymes that specifically modify the arginine residues of versatile substrates in cells. The …

Protein arginine methyltransferase 5 (PRMT5) as an anticancer target and its inhibitor discovery

Y Wang, W Hu, Y Yuan - Journal of medicinal chemistry, 2018 - ACS Publications
PRMT5 is a major enzyme responsible for symmetric dimethylation of arginine residues on
both histone and non-histone proteins, regulating many biological pathways in mammalian …

[HTML][HTML] PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma

J Wang, C Wang, P Xu, X Li, Y Lu, D Jin, X Yin… - Theranostics, 2021 - ncbi.nlm.nih.gov
Abstract Background and Objective: Epigenetic alterations are common events in clear cell
renal cell carcinoma (ccRCC), and protein arginine methyltransferase 1 (PRMT1) is an …

[HTML][HTML] PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism

M Sun, L Li, Y Niu, Y Wang, Q Yan, F Xie, Y Qiao… - … Pharmaceutica Sinica B, 2023 - Elsevier
Metabolic reprogramming is a hallmark of cancer, including lung cancer. However, the exact
underlying mechanism and therapeutic potential are largely unknown. Here we report that …

Protein arginine methyltransferases as therapeutic targets in hematological malignancies

C Sauter, J Simonet, F Guidez, B Dumétier, B Pernon… - Cancers, 2022 - mdpi.com
Simple Summary This review summarizes the current findings about the cellular roles of
protein arginine methyltransferases (PRMTs) in the formation of blood cells from stem cell …

Computer-aided drug design in epigenetics

W Lu, R Zhang, H Jiang, H Zhang, C Luo - Frontiers in chemistry, 2018 - frontiersin.org
Epigenetic dysfunction has been widely implicated in several diseases especially cancers
thus highlights the therapeutic potential for chemical interventions in this field. With rapid …